红细胞生成
聚乙二醇化
医学
药物开发
重症监护医学
生物信息学
药品
药理学
贫血
生物
生物技术
内科学
体内
作者
Iain C. Macdougall,Kai‐Uwe Eckardt
出处
期刊:The Lancet
[Elsevier BV]
日期:2006-08-18
卷期号:368 (9539): 947-953
被引量:144
标识
DOI:10.1016/s0140-6736(06)69120-4
摘要
As with many other therapeutic areas in modern-day medicine, scientific advances in drug development (using such techniques as recombinant DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and gene transfer) have resulted in the development of potential new agents and strategies for stimulating erythropoiesis. These advances are of possible benefit in treating anaemia due to various causes, including chronic renal failure. Several new treatments will soon become clinically available, while others are at present at an early stage of development but are nevertheless of scientific interest. We review these new therapeutic strategies, and discuss at what stage some of the newer products are in relation to their clinical development programme.
科研通智能强力驱动
Strongly Powered by AbleSci AI